+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06864013

Study of Short-course Radiotherapy with CAPEOX Chemotherapy plus Iparomlimab and Tuvonralimab Versus CAPEOX Alone in Patients Aged 18 to 75 with Locally Advanced Rectal Cancer Showing Microsatellite Stability or Proficient Mismatch Repair

Led by First Affiliated Hospital of Zhejiang University · Updated on 2026-01-14

116

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related death. This research is focused on patients with locally advanced rectal cancer LARC who have tumors classified as T3-4N without distant metastasis and have stable microsatellite status MSS or proficient mismatch repair pMMR. The trial aims to assess the effectiveness and organ preservation rates of a new neoadjuvant treatment combining short-course radiotherapy with chemotherapy and two immunotherapy drugs, Iparomlimab and Tuvonralimab, and to explore potential biomarkers predicting complete response within this immunotherapy-based total neoadjuvant therapy. Participants are randomly assigned to one of two groups. The experimental group receives short-course radiotherapy followed by four cycles of CAPEOX chemotherapy combined with Iparomlimab and Tuvonralimab. Those who undergo surgery will continue with four cycles of CAPEOX plus both immunotherapy drugs and then receive Iparomlimab and Tuvonralimab for up to one year. The control group receives the same radiotherapy followed by four cycles of CAPEOX chemotherapy alone, with additional chemotherapy after surgery if performed. Patients with clinical complete or near-complete remission may have surgery or a watch-and-wait approach to preserve organ function. During the study, participants undergo imaging, colonoscopy, and pathology to evaluate response. Researchers monitor outcomes including complete response rates, organ preservation, survival, and disease progression over up to 100 months. Safety and treatment tolerance are closely tracked, with treatment stopping if disease progresses or surgery is not possible. The study involves multiple centers and follows participants through treatment and follow-up to assess long-term results.

CONDITIONS

Brief Title

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

Research Team

G

Guosheng Wu, MD

W

Weiqin Jiang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here